Understanding anticoagulation therapy for stroke prevention and atrial fbrillation

Natalie Schellack, Senior Lecturer, Heleen Esterhuizen, Gustav Schellack

Research output: Contribution to journalLiterature reviewpeer-review

1 Citation (Scopus)

Abstract

Atrial fibrillation (AF) is a common cardiac rhythm disorder and patients with this condition are at an increased risk of strokes and other thromboembolic events. Available treatment options for the prevention of strokes in patients with AF include warfarin, aspirin and the novel oral anticoagulants (NOACs). Warfarin and aspirin reduce the risk of strokes in patients with AF and have been studied extensively. The NOACs are slowly beginning to make their way onto the South African market and are specifically highlighted in this article. © Medpharm.
Original languageEnglish
Pages (from-to)13-19
Number of pages7
JournalSA Pharmaceutical Journal
Publication statusPublished - 7 Oct 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Understanding anticoagulation therapy for stroke prevention and atrial fbrillation'. Together they form a unique fingerprint.

Cite this